$650,000.00 in Sales Expected for Synlogic Inc (NASDAQ:SYBX) This Quarter

Equities research analysts expect that Synlogic Inc (NASDAQ:SYBX) will post sales of $650,000.00 for the current quarter, Zacks reports. Five analysts have issued estimates for Synlogic’s earnings. The lowest sales estimate is $300,000.00 and the highest is $1.60 million. Synlogic posted sales of $110,000.00 during the same quarter last year, which would indicate a positive year-over-year growth rate of 490.9%. The business is expected to announce its next earnings report on Tuesday, March 10th.

According to Zacks, analysts expect that Synlogic will report full year sales of $1.52 million for the current financial year, with estimates ranging from $1.00 million to $2.59 million. For the next financial year, analysts forecast that the company will post sales of $1.49 million, with estimates ranging from $1.20 million to $2.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Synlogic.

Synlogic (NASDAQ:SYBX) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.09. Synlogic had a negative net margin of 4,574.82% and a negative return on equity of 34.49%. The firm had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.46 million.

SYBX has been the topic of several research reports. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 price objective (down previously from $10.00) on shares of Synlogic in a report on Wednesday, November 13th. Citigroup lowered shares of Synlogic from a “buy” rating to a “sell” rating and dropped their price objective for the company from $20.00 to $2.00 in a report on Wednesday, August 21st. Wedbush reiterated an “outperform” rating and set a $20.00 price objective on shares of Synlogic in a report on Friday, August 9th. Oppenheimer lowered shares of Synlogic from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 20th. Finally, Zacks Investment Research upgraded shares of Synlogic from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a report on Saturday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.69.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Synlogic by 11.1% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 37,208 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 3,708 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Synlogic by 17.1% in the 2nd quarter. Northern Trust Corp now owns 201,613 shares of the biotechnology company’s stock worth $1,835,000 after acquiring an additional 29,401 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of Synlogic in the 2nd quarter worth about $195,000. BlackRock Inc. raised its holdings in shares of Synlogic by 9.4% in the 2nd quarter. BlackRock Inc. now owns 1,317,063 shares of the biotechnology company’s stock worth $11,986,000 after acquiring an additional 113,665 shares during the last quarter. Finally, Flagship Harbor Advisors LLC acquired a new stake in shares of Synlogic in the 3rd quarter worth about $34,000. Institutional investors own 65.64% of the company’s stock.

Shares of NASDAQ SYBX traded up $0.14 during trading on Friday, hitting $2.10. 93,671 shares of the company traded hands, compared to its average volume of 144,104. The business’s fifty day moving average is $2.18 and its 200 day moving average is $5.23. Synlogic has a fifty-two week low of $1.91 and a fifty-two week high of $11.43. The firm has a market capitalization of $67.81 million, a price-to-earnings ratio of -1.03 and a beta of 2.56. The company has a debt-to-equity ratio of 0.14, a quick ratio of 12.70 and a current ratio of 12.70.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Featured Story: What causes a stock to be most active?

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.